Clinical trials: End-Stage Kidney Disease
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Uremic Pruritus
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
- Trial name
- NCT03998163
- Testing
- CR845 0.5 mcg/kg
- Where
- 47 sites in United States, Czechia and 2 more
- Volunteers
- 222 people
- Sponsor
- Cara Therapeutics, Inc.
Signs and Symptoms of Exit Site Infection, Physical Damage of the Tenckhoff Catheter
The Effects of Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients
The present study aims to compare the differences in exit site infection between patients receiving spray dressing and conventional care.
- Conditions
- Signs and Symptoms of Exit Site Infection, Physical Damage of the Tenckhoff Catheter, Skin Allery
- Trial name
- JUCspray (NCT01952964)
- Testing
- JUC spray dressing
- Where
- Hong Kong
- Volunteers
- 78 people
- Sponsor
- The Queen Elizabeth Hospital
Hypertension, Chronic Kidney Disease
Genetic Testing to Understand and Address Renal Disease Disparities
In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of…
- Conditions
- Hypertension, Chronic Kidney Disease, Genomics
- Trial name
- GUARDD (NCT02234063)
- Testing
- Immediate Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 2,052 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
End-Stage Kidney Disease, Hemodiafiltration
Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration
This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney…
- Conditions
- End-Stage Kidney Disease, Hemodiafiltration, Chronic Hemodialysis, Renal Failure
- Trial name
- CITRA-HDF (NCT07618858)
- Testing
- Regional citrate anticoagulation, Unfractionated heparin
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
Hyperphosphatemia
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
- Trial name
- NCT01518387
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 11 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Bayer
End Stage Renal Disease
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
- Trial name
- RMFPC-12 (NCT02636049)
- Testing
- Triferic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rockwell Medical Technologies, Inc.
Kidney Disease
Safety Evaluation of Use Sodic Enoxaparin
The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory…
- Trial name
- Enoxaparin (NCT00673426)
- Testing
- Enoxaparin sodic
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Delayed Graft Function, End Stage Renal Disease
Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Conditions
- Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
- Trial name
- NCT07020832
- Testing
- Pegcetacoplan
- Where
- Brazil
- Sponsor
- Apellis Pharmaceuticals, Inc.
Venous Stenosis, Venous Occlusion
The Solaris DE Sirolimus-Eluting Covered Stent for the Treatment of AV Access Stenosis or Occlusion
The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris Drug-Eluting Covered Stent (Solaris DE) in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including…
- Conditions
- Venous Stenosis, Venous Occlusion, Chronic Renal Failure
- Trial name
- DEScover (NCT06096142)
- Testing
- Solaris DE, PTA, Solaris DE (200)
- Where
- 5 sites in Brazil
- Volunteers
- 160 people
- Sponsor
- Scitech Produtos Medicos SA
End Stage Renal Disease
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm.
- Trial name
- NCT01395823
- Testing
- ergocalciferol supplementation
- Where
- 12 sites in United States
- Volunteers
- 470 people
- Sponsor
- Dialysis Clinic, Inc.
End Stage Renal Disease
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus
The purpose of this study is to learn if conversion from immediate release tacrolimus to Envarsus improves cerebral blood flow, brain blood flow response to exercise, and cognition.
- Trial name
- NCT03703154
- Testing
- Envarsus, Tacrolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Chronic Kidney Disease Requiring Chronic Dialysis
Reduction of Oxalate and Inflammation by Hemodiafiltration vs. Hemodialysis
The health care burden of CKD is substantial and growing with 10-15% of the population affected in both developed and developing countries.
- Trial name
- NCT02684656
- Testing
- Hemodialysis, Hemodiafiltration
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 1 (NCT00598273)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 490 people
- Sponsor
- Affymax
End Stage Renal Disease
Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)
To conduct a pragmatic randomized clinical trial in which the researchers will determine the mortality impact of a protocol whereby all hemodialysis patients receive an oral, protein-based nutritional supplement during the…
- Trial name
- HELPS-HD (NCT02933151)
- Testing
- Nutritional Supplement
- Where
- 2 sites in United States
- Volunteers
- 10,457 people
- Sponsor
- Dialysis Clinic, Inc.
Renal Impairment, Hemodialysis
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
- Trial name
- NCT05099445
- Testing
- INCB000928
- Where
- 5 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Diabetes, Chronic Kidney Disease
Glycaemic Response to Oral Nutrition Support During Haemodialysis
Patients with kidney, or renal, failure require life-saving treatment with regular dialysis. Dialysis is a form of treatment that simulates some kidney functions; to remove harmful waste products and extra water from the blood.
- Conditions
- Diabetes, Chronic Kidney Disease, End Stage Renal Failure on Dialysis
- Trial name
- GRO-HD (NCT02989688)
- Testing
- Nepro HP (Abbott Nutrition), Fortisip compact protein 125 ml + Calogen 20ml (Nutricia), Fortisip compact 125 ml (Nutricia)
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- King's College Hospital NHS Trust
Hypertension
Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure
This project aims at investigating the genetic, genomic and proteomic basis of hypertension and susceptibility to hypertension-related end organ damage (renal damage and heart failure).
- Trial name
- Hypercare (NCT02430805)
- Testing
- dna extraction and genotyping
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.